SKAN Group (SKAN) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
26 Aug, 2026Executive summary
Achieved strong growth in H1 2026, with all key financial metrics improving year-over-year, including order intake up 16.3% to CHF 247.6 million and net sales up 22.2% to CHF 165.5 million, driven by robust U.S. demand, organic growth, and acquisitions.
Profitability improved significantly: EBITDA reached CHF 15.3 million (margin 9.3%, up from CHF 0.9 million), and net profit was CHF 5.4 million, reflecting a turnaround from a prior-year loss.
Order backlog increased 27.8% to CHF 442.3 million, providing strong revenue visibility through 2028.
Both Equipment & Solutions and Services & Consumables segments contributed positively, with Services & Consumables now accounting for nearly 40% of group net sales.
Major project wins, successful acquisitions, and the delivery of digital twin projects enhanced differentiation and future growth prospects.
Financial highlights
Order intake: CHF 247.6 million, up 16.3% year-over-year; order backlog: CHF 442.3 million, up 27.8%.
Net sales: CHF 165.5 million, up 22.2% year-over-year (24% at constant FX); organic growth 13.3%.
EBITDA: CHF 15.3 million (margin 9.3%), up from CHF 0.9 million (margin 0.7%) in prior year.
Net profit: CHF 5.4 million for H1 2026; EBIT margin rose to 5.3% (from -3.6%).
Operating cash flow CHF 16.3 million; free cash flow CHF 2.7 million; cash balance CHF 88.5 million.
Outlook and guidance
Full-year 2026 guidance confirmed: net sales growth in the high teens and EBITDA margin between 13% and 15%.
Solid order backlog and market trends support confidence in achieving full-year and mid-term targets.
Focus remains on innovation, operational excellence, margin improvement, backlog execution, and cost discipline.
Pre-Approved Services expected to generate meaningful revenue starting next year, ramping up over 3-4 years.
Latest events from SKAN Group
- Order intake and backlog rose, sales and EBITDA fell, but 2026 outlook is strong with margin recovery.SKAN
H2 2025 - Record order intake and backlog offset lower sales and EBITDA, supporting a positive outlook.SKAN
H1 2025 - Strong growth in aseptic solutions driven by injectable biotech trends and innovation leadership.SKAN
Investor Presentation - Net sales up 17.2%, EBITDA margin within guidance, and robust order backlog support outlook.SKAN
H1 2024 - 76% stake acquisition boosts digital transformation and market reach in life sciences.SKAN
M&A Announcement - Digital integration, pre-approved services, and innovation drive growth and market leadership.SKAN
CMD 2025 - Order intake up 21.8%, EBITDA margin 15.8%, and dividend up 14% to CHF 0.40 per share.SKAN
H2 2024